P.3.c.034 A 6-month naturalistic study of outcome in schizophrenic out-patients, treated with olanzapine

Abstract

The study objectives were to evaluate the efficacy, safety, tolerability, and pharmacokinetics of RP5063 versus placebo. The study was conducted in adults with acute exacerbation of schizophrenia or schizoaffective disorder. This 28-day, multicenter, placebo-controlled, double-blind study randomized 234 subjects to RP5063 15, 30, or 50 mg; aripiprazole; or placebo (3:3:3:1:2) once daily. The aripiprazole arm was included solely to show assay sensitivity and was not powered to show efficacy. The primary endpoint was change from baseline to Day 28/EOT (End-of-Treatment) in Positive and Negative Syndrome Scale (PANSS) total score; secondary endpoints included PANSS subscales, improvement ≥ 1 point on the Clinical Global Impressions-Severity (CGI-S), depression and cognition scales.The primary analysis of PANSS Total showed improvement by a mean (SE) of − 20.23 (2.65),− 15.42 (2.04), and − 19.21 (2.39) in the RP5063 15, 30, and 50 mg arms, versus − 11.41 (3.45) in the placebo arm. The difference between treatment and placebo reached statistical significance for the 15 mg (p = 0.021) and 50 mg (p = 0.016) arms.Improvement with RP5063 was also seen for multiple secondary efficacy outcomes. Discontinuation for any reason was much lower for RP5063 (14%, 25%, 12%) versus placebo (26%) and aripiprazole (35%). The most common treatment-emergent adverse events (TEAE) in the RP5063 groups were insomnia and agitation. There were no significant changes in body weight, electrocardiogram, or incidence of orthostatic hypotension; there was a decrease in blood glucose, lipid profiles, and prolactin levels.In conclusion, the novel dopamine serotonin stabilizer, RP5063 is an efficacious and well-tolerated treatment for acute exacerbation of schizophrenia or schizoaffective disorder.